Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial

Launched by MURDOCH CHILDRENS RESEARCH INSTITUTE · Nov 11, 2024

Keywords

ClinConnect Summary

The ARISE Trial is studying how a special education program can help people aged 14-29 manage their allergic rhinitis, commonly known as hay fever. This condition can cause annoying symptoms like sneezing, a runny nose, and itchy eyes, and it affects many people in Australia. The trial aims to see if providing better education about how to use treatments like nasal sprays can reduce these symptoms and improve the overall quality of life for those with moderate to severe hay fever. Many young people don’t use their medications correctly because they lack proper guidance and may worry about side effects, so this study hopes to change that.

To be eligible for the trial, participants must be between 14 and 29 years old and have been diagnosed with moderate to severe allergic rhinitis. They also need to be prescribed specific nasal sprays for their treatment. Throughout the study, participants will receive detailed education on managing their condition and using their medications effectively. This trial is not yet recruiting participants, but it aims to make a positive impact not just on individual lives, but also on families and the healthcare system by improving the way allergic rhinitis is managed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adolescents and young adults aged 14-29 years diagnosed by their treating clinician with moderate to severe AR (defined by ARIA guidelines if AR symptoms significantly affect sleep or activities of daily living, and/or if they are considered bothersome (15)) at a participating recruitment site by symptomatology and positive SPT to at least one aeroallergen and has been prescribed/recommended Dymista or Ryaltris 2. Ability to understand and comply with study requirements and provide informed consent
• Exclusion Criteria:
• • 1. Current or previous treatment for AR with aeroallergen immunotherapy (patients will be specifically asked if they have ever received subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) for aeroallergens such as pollen, house dust mite, cats, dogs and horses)